<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title><![CDATA[Gastric Cancer]]></title>
    <link>https://www.leadingmarketresearch.com/pharmaceuticals-biotechnology/pharmaceuticals/therapeutic-areas/cancer/gastric-cancer</link>
    <description><![CDATA[Gastric Cancer]]></description>
    <pubDate>Thu, 25 Jun 2026 07:59:56 +0000</pubDate>
    <generator>Zend_Feed</generator>
    <docs>http://blogs.law.harvard.edu/tech/rss</docs>
    <item>
      <title><![CDATA[Gastric Cancer - Pipeline Review, H1 2020]]></title>
      <link>https://www.leadingmarketresearch.com/gastric-cancer-pipeline-review-h1-2020</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H1 2020, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.<br><br>Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy. <br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and mo...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-214859"><span class="price">$2,500.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Thu, 07 May 2020 13:13:49 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Gastric Ulcers - Pipeline Review, H2 2019]]></title>
      <link>https://www.leadingmarketresearch.com/gastric-ulcers-pipeline-review-h2-2019</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Gastric Ulcers - Pipeline Review, H2 2019, provides an overview of the Gastric Ulcers (Gastrointestinal) pipeline landscape.<br><br>Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nausea or vomiting and unexplained weight loss. Predisposing factors include smoking and alcoholism. Treatment includes antibiotics and antacids. <br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Gastric Ulcers - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Gastric Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and develo...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-212636"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 11 Dec 2019 11:13:09 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Gastric Cancer - Pipeline Review, H2 2018]]></title>
      <link>https://www.leadingmarketresearch.com/gastric-cancer-pipeline-review-h2-2018</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H2 2018, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.<br><br>Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy. <br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and mo...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-204969"><span class="price">$2,500.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Thu, 29 Nov 2018 15:00:25 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017]]></title>
      <link>https://www.leadingmarketresearch.com/gastric-and-esophageal-cancer-drug-development-pipeline-review-2017</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>This report provides an overview of the Gastric and Esophageal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for each of these cancer types, and features dormant and discontinued projects.<br><br>Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. There are a total of 322 products in development for this indication, by 208 companies and 22 academic institutions. Key companies operating in this pipeline space include Eli Lilly, Roche, Bristol-Myers Squibb, Incyte, Pfizer and AstraZeneca.<br><br>Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. There are a to...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-200299"><span class="price">$3,995.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 17 Jan 2018 12:12:43 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Gastric Cancer  - Market Insights, Epidemiology and Market Forecast-2023]]></title>
      <link>https://www.leadingmarketresearch.com/gastric-cancer-market-insights-epidemiology-and-market-forecast-2023</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;">Note*: This report requires 7-10 business days to complete.

DelveInsight’s Gastric Cancer - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Crohn’s disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Gastric Cancer forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Gastric Cancer till 2023. 

Key Coverage and Benefits

• The report will help in developing business strategies by understanding the trends shaping and driving the global Gastric Cancer market. 
• Identifying patient populations in the global “Gastric Cancermarket to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Gastric Cancer therapeutics in each of the markets covered.
• To understand th...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-195219"><span class="price">$4,950.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 25 Apr 2017 20:08:12 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Gastric Cancer Global Clinical Trials Review, H1, 2016]]></title>
      <link>https://www.leadingmarketresearch.com/gastric-cancer-global-clinical-trials-review-h1-2016</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>GlobalData&#039;s clinical trial report, “Gastric Cancer Global Clinical Trials Review, H1, 2016&quot; provides an overview of Gastric Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Gastric Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.<br><br>The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive ad...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-179587"><span class="price">$2,500.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Thu, 23 Jun 2016 09:26:10 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs]]></title>
      <link>https://www.leadingmarketresearch.com/frontier-pharma-gastric-cancer-early-stage-pipeline-innovation-shows-shi</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Gastric cancer is the fifth most common cancer globally, and due to its indolent nature remains one of the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The gastric cancer market is undergoing a gradual change, from a focus on generic chemotherapy regimens to complex treatment landscape based on targeted therapies. Recently the market has witnessed the approval of efficacious therapies such as Cyramza, but this only benefits a small subset of patients. As the understanding of disease pathophysiology increases, new targets need to be identified and converted into improved therapeutic options. The current pipeline shows strong promise, as it shows a gradual shift from generic cytotoxic therapies to more diverse targeted therapies.<br><br><b>Scope</b><br><br>- What is the pathophysiology of gastric cancer?<br>- How is gastric cancer diagnosed?<br>- What are the current treatment options?<br>- What are the common targets and ...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-174181"><span class="price">$6,995.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 01 Jun 2016 12:01:40 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Gastric Cancer - Pipeline Review, H1 2016]]></title>
      <link>https://www.leadingmarketresearch.com/gastric-cancer-pipeline-review-h1-2016</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct’s, ‘Gastric Cancer - Pipeline Review, H1 2016’, provides an overview of the Gastric Cancer pipeline landscape. <br><br>The report provides comprehensive information on the therapeutics under development for Gastric Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. <br><br>Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor present...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-174138"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 31 May 2016 09:45:03 +0000</pubDate>
    </item>
  </channel>
</rss>
